EGFR and non-small cell lung carcinoma: Several other EGFR genetic alterations with oncogenic potential have been reported; for example, deletion mutants in glioblastoma multiforme (GBM; deletion of exons 2–7, denoted EGFRvIII) and in NSCLC (exon 19), and activating kinase domain mutations in NSCLC, for example, the leucine-to-argine substitution at position 858 (L858R; Rosell et al., 2007).